The purpose of the Psychiatric Genomics Consortium (PGC) is to unite investigators around the world to conduct meta- and mega-analyses of genome-wide genomic data for psychiatric disorders. This website provides information about the organization, implementation, and results of the PGC.
The PGC began in early 2007 and has rapidly become a collaborative confederation of most investigators in the field. The PGC includes over 800 investigators from 38 countries. There are samples from more than 900,000 individuals currently in analysis, and this number is growing rapidly. The PGC is the largest consortium and the largest biological experiment in the history of psychiatry.
The PGC is passionate about open, inclusive, participatory, and democratic science. Given the importance of the problems we study, we are committed to rapid progress.
From 2007-11, the PGC focused on autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder (BIP), major depressive disorder (MDD), and schizophrenia (SCZ). We now include large studies of eating disorders (ED), substance use disorders (SUD), obsessive-compulsive disorder (OCD)/Tourette’s Syndrome (TS), and post-traumatic stress disorder (PTSD). Initially, the PGC focused on common single nucleotide polymorphisms (SNPs). Our focus has expanded to include copy number variation (CNV) and uncommon/rare genetic variation.
The PGC has received funding from many sources. The PGC has relied heavily on the goodwill of its members and their donated effort. The establishment and genotyping of our primary studies was funded by a wide range of national, international, and commercial funders.
The Psychiatric Genomics Consortium is one of the most innovative experiments in the history of psychiatry. We have unified much of the field to enable rapid progress in elucidating the genetic basis of psychiatric disorders. We have 800+ investigators from 36 countries and >400K subjects. The PGC has attracted a cadre of outstanding scientists whose careers center on our work.
As of 2016 the PGC has published 17 main papers plus 31 secondary analysis/methods development papers. The most important was the landmark Nature paper identifying 108 loci for schizophrenia (SCZ 2014). Due to our open-source approach, there are 75+ papers that use PGC results, and we know of numerous groups that are using our findings to direct basic and applied research (including therapeutic development).
The PGC consists of the Coordinating Committee, nine disorder working groups (one each for ADHD, ASD, BIP, ED, MDD, OCD/TS, PTSD, SUD, and SCZ), a statistical analysis group (with a pathway analysis subgroup), and the cross-disorder group.
Background Papers by PGC Members
PGC members have written manuscript-length discussions of the rationale behind the PGC. These papers include:
- The “Big-Picture” Framework or Intent of the PGC
- A History of Genomic Studies in Psychiatry
- Description of the Rationale for Cross-Disorder Analysis
- A “Primer” of Basic Concepts in Genomics
- An Updated Review
- Although this is not from the PGC per se, this editorial calling for more GWAS in psychiatry was signed by 96 scientists in the field
PGC Publications on PubMed
Note: The majority of these search results are PGC publications. However, due to the search criteria some of the listed publications mention the PGC but are not PGC-associated publications.